EU Deal Tracker: Polpharma And JGL Join Forces, PharmaNutra Expands Reach, Bionorica Divests Cannabis Unit

Polphama and JGL have struck a deal to distribute one another's ophthalmology products, PharmaNutra has secured expanded distribution for its Cetilar joint pain product, and Bionorica has offloaded its cannabis business to Canada's Canopy.

EyeDrops
• Source: Shutterstock

Poland’s Polpharma SA and Croatia’s Jadran-Galenski Laboratorij d.d. (JGL) have joined forces to make their respective OTC products in the ophthalmology segment more widely available across Europe.

Through the firms’ collaboration, Polpharma will market across a number of European territories – including its home country – certain...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Europe

EU JCA: Milestone Report Shows Room For Improvement For Orphan Drugs And PICOs

In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By 

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

Marinomed Starts Restructuring Proceedings As Debts Mount

 
• By 

Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.

Perrigo Adds High-Strength Paracetamol To UK Solpadeine Line

 
• By 

Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative. 

More from Geography

Perrigo Securities Class-Action Settlement Awards Attorneys’ Fees, Expenses Lower Than Requested

 

Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.

Over The Counter: Exploring The Postbiotic Opportunity In Consumer Health, With Kerry’s Sonja Nodland

 
• By 

In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry. 

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By 

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.